Lipocine Inc

For the period ended Dec 31, 2024. Filed Mar 13, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 13, 2025

LPCN$1.72+9.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$6,205,926	$4,771,758
Marketable investment securities	15,427,385	17,263,788
Accrued interest income	120,447	52,254
Prepaid and other current assets	567,915	773,424
Total current assets	22,321,673	22,861,224
Property and equipment, net of accumulated depreciation of $1,223,297 and $1,182,191 respectively	165,075	116,095
Other assets	23,753	23,753
Total assets	$22,510,501	$23,001,072
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$271,696	$1,395,977
Accrued expenses	921,240	1,218,486
Deferred revenue	320,000	-
Warrant liability	-	17,166
Total current liabilities	1,512,936	2,631,629
Total liabilities	1,512,936	2,631,629
Commitments and contingencies (notes 8, 9 and 11)	-
Stockholders’ equity:
Common stock, par value $0.0001 per share, 200,000,000 shares authorized; 5,348,276 and 5,316,166 issued and 5,347,940 and 5,315,830 outstanding, respectively	8,863	8,860
Additional paid-in capital	220,789,138	220,171,250
Treasury stock at cost, 336 shares	(40,712)	(40,712)
Accumulated other comprehensive gain	9,138	7,259
Accumulated deficit	(199,768,862)	(199,777,214)
Total stockholders’ equity	20,997,565	20,369,443
Total liabilities and stockholders’ equity	$22,510,501	$23,001,072

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.